Clinical characteristics of pain syndrome in patients with multiple myeloma

Stamo, А. P.; Grigorieva, V.N.

doi:10.17116/jnevro201611610111-15

Cited by 5 publications

(2 citation statements)

References 19 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple Myeloma (MM) is a disabling cancer that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance to plasma cell leukemia. MM is characterized by several features, including low blood counts, bone and calcium problems, infections, kidney problems, monoclonal gammopathy, light chain amyloidosis and solitary plasmacytoma [1] .Thalidomide was first introduced for patients with refractory multiple myeloma. Due to the promising results achieved in these patients, the drug was subsequently used in the earlier stages of the disease [2] .…”

Section: Introductionmentioning

confidence: 99%

Avascular Necrosis of Humeral Head after Thalidomide Use: A Report of Two Cases

Rezaeian¹,

Internationals²

2018

IJHT

View full text Add to dashboard Cite

Background: Thalidomide is an immunomodulatory drug which is used for treatment of certain cancers such as multiple myeloma. Multiple Myeloma (MM) is a cancer that creates a specific type of white blood cell called plasma cell and accumulates these cancerous cells in bone marrow. To our knowledge, there is no report of avascular necrosis of humeral head after thalidomide use; hence, the aim of present study was to report two cases of avascular necrosis of humeral head after thalidomide use in MM patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Avascular Necrosis of Humeral Head after Thalidomide Use: A Report of Two Cases

Rezaeian¹,

Internationals²

2018

IJHT

View full text Add to dashboard Cite

show abstract

“…Multiple Myeloma (MM) is a disabling cancer that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance to plasma cell leukemia. MM is characterized by several features, including low blood counts, bone and calcium problems, infections, kidney problems, monoclonal gammopathy, light chain amyloidosis and solitary plasmacytoma [1]. Thalidomide was first introduced for patients with refractory multiple myeloma.…”

Section: Introductionmentioning

confidence: 99%

Avascular Necrosis of Humeral Head after Thalidomide Use: A Report of Two Cases

Rezaeian

2018

OPROJ

View full text Add to dashboard Cite

Radiographic evaluation: Standard radiological diagnoses include conventional x-ray images. True anterior-posterior (AP) view (Figure 1) showed subchondral sclerosis and a radiolucent Abstract Background: Thalidomide is an immunomodulatory drug which is used for treatment of certain cancers such as multiple myeloma. Multiple myeloma (MM) is a cancer that creates a specific type of white blood cell called plasma cell and accumulates these cancerous cells in bone marrow. To our knowledge, there is no report of avascular necrosis of humeral head after thalidomide use; hence, the aim of present study was to report two cases of avascular necrosis of humeral head after thalidomide use in MM patients.

show abstract

Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation

Ryabukhina

Zeynalovа

Тимофеева

et al. 2023

jour

View full text Add to dashboard Cite

Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.

show abstract

Clinical characteristics of pain syndrome in patients with multiple myeloma

Cited by 5 publications

References 19 publications

Avascular Necrosis of Humeral Head after Thalidomide Use: A Report of Two Cases

Avascular Necrosis of Humeral Head after Thalidomide Use: A Report of Two Cases

Avascular Necrosis of Humeral Head after Thalidomide Use: A Report of Two Cases

Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation

Contact Info

Product

Resources

About